Amycretin: one molecule that hits GLP-1 and amylin
Amycretin is an experimental Novo Nordisk drug that targets both GLP-1 and amylin in one molecule. Early trials show strong weight loss, but it is not approved and not available yet.
Imagine one medicine that does two hunger-taming jobs at once. That is the idea behind amycretin. It is a new, experimental drug from Novo Nordisk. It is not approved anywhere, not sold in India, and still years away. But the early science is exciting, so let us look at it honestly.
What amycretin does inside the body
Amycretin is called a dual agonist. That means one molecule switches on two receivers in the body. One receiver is GLP-1, the same target as semaglutide (Wegovy). The other is amylin, a hormone from the pancreas that, like GLP-1, tames appetite and slows stomach emptying (food leaves the stomach more slowly, so you feel full longer). Hitting both in one molecule could mean stronger weight loss than hitting either alone. Novo Nordisk is testing two forms: a once-weekly injection under the skin, and a once-daily tablet. Yes, an oral pill form is really in development.
Amycretin vs CagriSema — both hit GLP-1 and amylin
Amycretin is available now and you can buy it in India.
mostly falseMostly false. Amycretin is experimental. It is still in early-phase trials. It is NOT approved by any regulator, NOT sold anywhere, and NOT available in India. Do not trust any seller offering 'amycretin' online — it cannot be the real drug yet.
The early weight-loss numbers prove amycretin works better than everything else.
it dependsIt depends — explained simply. The numbers are exciting but very early and very small. In one phase 1b/2a injection trial of 125 people, the 60 mg weekly dose gave about 24.3% weight loss over 36 weeks, and weight loss had not plateaued yet. In a small oral trial of 144 people, the highest dose gave about 13.1% weight loss over 12 weeks. These are tiny early studies, not big phase 3 trials. They can look better or worse in larger studies. So the signal is promising, not proven.
What to do while amycretin is still being studied
The bottom line
Amycretin is a clever idea — one molecule hitting GLP-1 and amylin together, maybe even as a daily pill. Early trial numbers are exciting, but they are small and early. It is not approved, not sold, and not in India. Talk to your doctor about what is available today, and do not chase an experimental drug.